Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01287247 · ClinicalTrials.gov registry record
Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States
A clinical trial, sponsored by Merz North America.
- Completed
- Registry status
- 688
- Enrollment target
NCT01287247 is a clinical trial that has completed, run by Merz North America. The registered enrollment target is 688 participants.
The verdict
NCT01287247 has completed, sponsored by Merz North America.
- COMPLETED
- Registry status
- 688 participants
- Enrollment target
Study Summary
This is a prospective, observational trial evaluating the "real world" use of Xeomin®(incobotulinumtoxinA). Physicians may enroll patients who are eligible to be treated with a botulinum toxin for cervical dystonia or blepharospasm based upon their clinical experience. The physician must have chosen to treat the patient with Xeomin® (incobotulinumtoxinA) prior to and independent of enrollment in this study. Physicians may choose to treat their subjects with up to 2 treatment cycles (approximately 6 months/subject) of Xeomin® (incobotulinumtoxinA) at a dose determined by the physician based upon his/her clinical experience with botulinum toxin. According and dependent on clinical practice, the investigators expect that subjects will be seen by the investigator for an average of 3 visits (two treatment cycles).
Interventions
- BIOLOGICAL Xeomin®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 688 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01287247
The ClinicalTrials.gov registry entry for NCT01287247 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 688 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz North America, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xeomin® is the first listed.
NCT01287247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01287247 about?
NCT01287247 is a clinical study titled "Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States". This is a prospective, observational trial evaluating the "real world" use of Xeomin®(incobotulinumtoxinA). Physicians may enroll patients who are eligible to be treated with a botulinum toxin for cervical dystonia or blepharospasm based upon their clinical experience. The physician must have chosen...
What is the current status of trial NCT01287247?
This trial is currently completed. The enrollment target is 688 participants. The study started on 2011-02. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01287247?
The interventions under investigation include: Xeomin® (BIOLOGICAL).
Who is sponsoring clinical trial NCT01287247?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.